在代谢功能障碍相关的脂肪肝疾病中,不同饮食模式对代谢概况和肝功能的比较疗效:一个网络元分析
Jiahui Zou1, Fei Tian2, Shuqing Cui1
1Department of Hepatobiliary Surgery, KaiLuan General Hospital, North China University of Science and Technology, Tangshan, Hebei, China.
BMC gastroenterology
|December 10, 2025
概括
间歇性禁食 (IF) 在代谢功能障碍相关的脂肪肝 (MAFLD) 患者中有效降低体重和腰围. 地中海饮食 (MD) 在改善肝脏脂肪和脂质特征方面表现有前途,这表明MAFLD管理的个性化饮食方法.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢障碍 代谢障碍 代谢障碍
- 营养科学 营养科学
背景情况:
- 与代谢功能障碍相关的脂肪肝疾病 (MAFLD) 是一个日益严重的全球健康问题.
- 饮食干预是MAFLD管理的核心.
- 这项研究比较了四种饮食:地中海饮食 (MD),间歇性禁食 (IF),停止高血压的饮食方法 (DASH) 和低脂肪饮食 (LF).
研究的目的:
- 评估四种饮食模式在患有MAFLD的成年人中的比较有效性.
- 评估对肝功能和代谢概况的影响.
- 为了确定MAFLD治疗的最佳饮食策略.
主要方法:
- 一个系统的网络元分析,遵循PRISMA指南.
- 搜索了多个数据库,查找到2025年10月的随机对照试验 (RCT).
- 使用Cochrane风险偏差工具2.0评估研究质量,并使用SUCRA对干预措施进行排名.
主要成果:
- 间歇性禁食 (IF) 在减肥 (WMD = -1.96 kg) 和减小腰围 (WMD = -1.73 cm) 中最有效.
- 密集的IF疗法比时间限制的养更有好处.
- 地中海饮食 (MD) 显著降低了肝内脂质 (IHL) (WMD = -1.68%) 和甘油三 (WMD = -22.54 mg/dL).
结论:
- IF和MD对MAFLD具有明显的治疗益处.
- IF在体重管理方面表现出色,而MD针对肝硬化和脂质疾病.
- 根据患者的代谢特征推个性化的饮食策略,等待进一步的研究.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
200
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
200
Overview of Fatty Acid Metabolism
36.2K
Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
36.2K
Ultrasound II: Endoscopic Ultrasound and FibroScan
499
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
499
Overview of Lipid Metabolism
4.7K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.7K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
159
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
159


